Cite
Bamba R, Okamura T, Hashimoto Y, et al. Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice. J Cachexia Sarcopenia Muscle. 2021;doi: 10.1002/jcsm.12814.
Bamba, R., Okamura, T., Hashimoto, Y., Majima, S., Senmaru, T., Ushigome, E., Nakanishi, N., Asano, M., Yamazaki, M., Takakuwa, H., Hamaguchi, M., & Fukui, M. (2021). Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice. Journal of cachexia, sarcopenia and muscle, . https://doi.org/10.1002/jcsm.12814
Bamba, Ryo, et al. "Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice." Journal of cachexia, sarcopenia and muscle vol. (2021). doi: https://doi.org/10.1002/jcsm.12814
Bamba R, Okamura T, Hashimoto Y, Majima S, Senmaru T, Ushigome E, Nakanishi N, Asano M, Yamazaki M, Takakuwa H, Hamaguchi M, Fukui M. Extracellular lipidome change by an SGLT2 inhibitor, luseogliflozin, contributes to prevent skeletal muscle atrophy in db/db mice. J Cachexia Sarcopenia Muscle. 2021 Dec 02; doi: 10.1002/jcsm.12814. Epub 2021 Dec 02. PMID: 34854254.
Copy
Download .nbib